Here, we will cover the key findings and effectors of IMP2 action in colorectal cancer, breast cancer, leukemia and lymphoma, hepatocellular carcinoma, lung adenocarcinoma, ovarian malignancies, endometrial cancer, oral cancer, renal cell carcinoma, thyroid cancer, and glioblastoma. Here, IGF2BP2 is linked to renal cell carcinoma.